Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, May 23, 2016

External Validation of the ASTRAL and DRAGON Scores for Prediction of Functional Outcome in Stroke

Prediction models won't get any better until objective points are used. 3d representation of the dead and penumbra or bleed areas and location of the epicenter. That way you would at least have a decent starting point so clinical trials can be compared. The Rankin scale has no useful discrimination at all.
There seems to be no point in even doing this prediction, I can see no use for survivors at all except as a way to deny therapy.
http://stroke.ahajournals.org/content/early/2016/05/12/STROKEAHA.116.012802.abstract?sid=8aed9298-344e-4c0e-88de-190cae36e5ff
  1. Niaz Ahmed, MD, PhD
+ Author Affiliations
  1. From the Department of Clinical Neurosciences, Karolinska Institutet and Department of Neurology Karolinska University Hospital, Stockholm, Sweden (C.C., M.M., N.W., N.A.); Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (M.B.); Stroke Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain (L.D.); Department of Neurology, 3rd Medical Faculty, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic (O.S.); Stroke Unit, Neurological Department, Regional Hospital, Jihlava, Czech Republic (O.S.); Emergency Department Stroke Unit, Hospital Policlinico Umberto I, Department of Neurology and Psychiatry, Sapienza University, Rome, Italy (D.T.); and Department of Medicine, Institute for Ageing and Health (Stroke Research Group), Newcastle University, Newcastle Upon Tyne, United Kingdom (G.A.F.).
  1. Correspondence to Charith Cooray, MD, Karolinska Stroke Research Unit, Department of Neurology Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden. E-mail charith.cooray@karolinska.se
  1. Presented in part at the European Stroke Organization Conference, Barcelona, Spain, May 10–12, 2016.

Abstract

Background and Purpose—ASTRAL (Acute Stroke Registry and Analysis of Lausanne) and DRAGON (includes dense middle cerebral artery sign, prestroke modified Rankin Scale score, age, glucose, onset to treatment, National Institutes of Health Stroke Scale score) are 2 recently developed scores for predicting functional outcome after acute stroke in unselected acute ischemic stroke patients and in patients treated with intravenous thrombolysis, respectively. We aimed to perform external validation of these scores to assess their predictive performance in the large multicentre Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register.
Methods—We calculated the ASTRAL and DRAGON scores in 36 131 and 33 716 patients, respectively, registered in Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register between 2003 and 2013. The proportion of patients with 3-month modified Rankin Scale scores of 3 to 6 was observed for each score point and compared with the predicted proportion according to the risk scores. Calibration was assessed using calibration plots, and predictive performance was assessed using area under the curve of the receiver operating characteristic. Multivariate logistic regression coefficients for the variables in the 2 scores were compared with the original derivation cohorts.
Results—The ASTRAL showed an area under the curve of 0.790 (95% confidence interval, 0.786–0.795) and the DRAGON an area under the curve of 0.774 (95% confidence interval, 0.769–0.779). All ASTRAL parameters except range of visual fields and all DRAGON parameters were significantly associated with functional outcome in multivariate analysis.
Conclusions—The ASTRAL and DRAGON scores show an acceptable predictive performance. ASTRAL does not require imaging-data and therefore may have an advantage for the use in prehospital patient assessment. Prospective studies of both scores evaluating the impact of their use on patient outcomes after intravenous thrombolysis and endovascular therapy are needed.

No comments:

Post a Comment